{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.35","upperLimit":"5.52","value":"2.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral sunitinib malate once daily on days 1-42. Treatment repeats every 42 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (Kinase Inhibitor Therapy)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from registration to progression or death due to any cause, assessed up to 3 years","title":"Event-free Survival","type":"SECONDARY","unitOfMeasure":"months"}